Together these findings demonstrate that inhibiting MPO could represent a viable therapeutic strategy to dampen oxidative stress in XDP, although future studies need to determine whether decreasing ROS could prevent or reduce neurodegeneration and demonstrate clinical benefit. Here, MPO is linked to X-linked dystonia-parkinsonism.